Adalimumab Biosimilar SB5 Effective in Behçet’s Syndrome-Related Uveitis and IBD, Studies Find
January 27th 2022Two new studies have investigated the adalimumab biosimilar SB5 (Imraldi; Samsung Bioepis) in inflammatory bowel disease (IBD; Crohn’s disease and ulcerative colitis) and non-anterior uveitis associated with Behcet's syndrome (BS).